What is STEQEYMA? What is Steqeyma used for? Uses, Dosage and Side Effects!

Описание к видео What is STEQEYMA? What is Steqeyma used for? Uses, Dosage and Side Effects!

What is STEQEYMA? What is Steqeyma used for?

Curious about Steqeyma? Learn about this biosimilar to Stelara, including its uses, dosage, and potential side effects in this informative video.

Introduction
Overview: Introduction to Steqeyma, its uses for treating autoimmune conditions like plaque psoriasis and Crohn’s disease.
Mechanism: Blocks IL12 and IL23 proteins to reduce inflammation and symptoms.

FDA Approval
Drug Class: Falls under interleukin inhibitors.
Approval: Approved as a biosimilar to Stellara for a range of conditions including psoriasis and arthritis.

Administration Guide
Supervision: Administered under doctor supervision, with instructions on handling and preparation.
Infusion Process: Initial dose via intravenous infusion, followed by subcutaneous injection in subsequent doses.

Pediatric Dosing
Guidelines: Detailed guidelines for dosing in children over 6 years old.
Weight-Based Dosing: Doses calculated based on body weight.

Crohn's Dosage
Initial and Maintenance Dosing: First dose as infusion; followed by subcutaneous injections.
Dosage Variability: Dependent on weight for both pediatric and adult patients.

Concluding Thoughts
General Guidance: Recap on dosage forms, side effects, and the importance of medical guidance during treatment.

00:00 Introduction
00:49 FDA Approval
02:10 Administration Guide
02:58 Pediatric Dosing
03:41 Crohn's Dosage
04:21 Concluding Thoughts

#steqeyma #whatissteqeyma #whatissteqeymausedfor #ustekinumabstba #ustekinumab #whatisustekinumab #whatisustekinumabusedfor #biosimilartostelara #autoimmunediseaseseym #psoriaticarthritis #crohnsdisease #biosimilarstellara #fdaapprovalsteqeyma #steqeymasideeffects #steqeymadosing #steqeymauses #ustekinumabmechanismofaction #ustekinumabuses #ustekinumabinjection #ustekinumabdosage #stelaraustekinumab #ustekinumabsideeffects #ustekinumabstelara

Комментарии

Информация по комментариям в разработке